Viewing nowCombinationJanuritin Combi Tablet 50/1000 Milligrams
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.

MFDS item code 202108199 · Approved 2021.12.30 · Insurance code 671807410
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood glucose levels in patients with type 2 diabetes. It is particularly effective for those who have not previously been treated with diabetes medications or for those who do not achieve adequate blood glucose control with monotherapy. It can be used when blood glucose control is difficult with metformin or sitagliptin monotherapy or to replace the use of both of these drugs together. Additionally, it may be added to therapy when blood glucose control is insufficient with metformin and sulfonylurea or metformin and thiazolidinedione combination therapy. It can also be used with insulin and metformin if blood glucose control remains challenging. Therefore, this medication is effectively used for blood glucose management in patients with type 2 diabetes who have difficulty with multiple treatment methods.
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication is used for diabetes treatment and contains two ingredients, sitagliptin and metformin. While taking this medication, allergic reactions may occur, so if symptoms such as a rash, difficulty breathing, or swelling of the face or neck appear, the medication should be discontinued immediately, and a doctor consulted. Serious inflammation of the pancreas known as pancreatitis may occur, so if symptoms such as abdominal pain, nausea, or vomiting arise during treatment, inform your healthcare provider without delay. This medication is not to be administered to patients with severely impaired kidney function, acute heart failure, serious infections, or dehydration. Administration should be temporarily halted before and after examinations using iodine contrast agents, and restarted only after normal kidney function is confirmed. Pregnant women, women who may become pregnant, and nursing mothers should not take this medication. Care should be taken for the rare complication of lactic acidosis, which may present with symptoms such as muscle pain, difficulty breathing, weakness, and abdominal pain, requiring immediate medical consultation if such symptoms occur. This medication carries a risk of hypoglycemia, especially when meals are skipped or intense exercise occurs; hypoglycemia symptoms may be more pronounced when taken with other blood glucose-lowering agents. Patients with impaired liver function or excessive alcohol consumption should be cautious when taking this medication. Regular monitoring of kidney function and blood tests during treatment is recommended, as well as periodic checks of vitamin B12 levels. Interactions may occur with other medications taken alongside this drug, so all medications being taken must be disclosed to a doctor or pharmacist. In cases of surgery, this medication should be stopped 48 hours prior to surgery and can only be resumed once normal kidney function is confirmed post-surgery. Elderly patients may require dose adjustments and regular testing, given potential declines in kidney function. In case of overdose, seek immediate medical attention for appropriate treatment, as blood dialysis may be beneficial. During treatment with this medication, patients should fully understand its benefits and risks, and consistently conduct regular blood glucose checks and health assessments.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the medication's efficacy over time.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.